# ClinicalTrials.gov record NCT03012594

> PeptideScanner retained ClinicalTrials.gov record NCT03012594 at 2026-07-30T20:07:13.495Z. Its registry update date was 2021-01-15, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct03012594-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-01-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03012594-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03012594-lanreotide-v1.json
- Content SHA-256: `3becbc3b33425028a30309bd4afef33ffc19abee7f22d722a63e6f8d78350030`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03012594 ([`ctg-observation-nct03012594-2021-01-15-ef231d4fa94a`](#source-ctg-observation-nct03012594-2021-01-15-ef231d4fa94a))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03012594 at 2026-07-30T20:07:13.495Z. Its registry update date was 2021-01-15, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03012594-2021-01-15-ef231d4fa94a`](#source-ctg-observation-nct03012594-2021-01-15-ef231d4fa94a))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03012594 at 2026-07-30T20:07:13.495Z. Its registry update date was 2021-01-15, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03012594-2021-01-15-ef231d4fa94a`](#source-ctg-observation-nct03012594-2021-01-15-ef231d4fa94a))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03012594-2021-01-15-ef231d4fa94a`](#source-ctg-observation-nct03012594-2021-01-15-ef231d4fa94a))

## Sources

<a id="source-ctg-observation-nct03012594-2021-01-15-ef231d4fa94a"></a>
- **ClinicalTrials.gov record NCT03012594 · retained source version 2021-01-15:ef231d4fa94a131d748fb2b03d110d53ede9fb393aaa0073c5e01de9fa760108** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03012594) (`ctg-observation-nct03012594-2021-01-15-ef231d4fa94a`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03012594." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03012594-lanreotide-v1.json SHA-256: 3becbc3b33425028a30309bd4afef33ffc19abee7f22d722a63e6f8d78350030.